Arcellx, INC 10-Q quarterly reports

Arcellx reported significantly increased net losses for Q3 and 9M 2025, driven by higher operating expenses and reduced collaboration revenue, while maintaining a cash runway into 2028.

Arcellx reports increased net losses in Q2 2025 despite a strong cash position, as collaboration revenue declines and R&D expenses rise for its cell therapy pipeline.

Arcellx's Q1 2025 shows a decrease in collaboration revenue and a significant increase in research and development expenses, leading to a larger net loss compared to Q1 2024.

Arcellx reports a net loss of $60.3 million for the nine months ended September 30, 2024, while highlighting progress in clinical trials and collaborations.

Arcellx, a clinical-stage biopharmaceutical company, announced its second quarter 2024 financial results, highlighting progress in its cell therapy programs and collaboration with Kite Pharma.

Arcellx's first quarter 2024 results show a significant increase in collaboration revenue, driven by its partnership with Kite Pharma, while the company continues to advance its clinical programs.